LCM
TVTX icon

Lynx1 Capital Management’s Travere Therapeutics TVTX Stock Holding History

Lynx1 Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-411,680
Closed -$10.6M – 14
2022
Q1 		$10.6M Sell
411,680
-325,381
-44% -$8.64M 9.85% 5
2021
Q4 		$22.9M Buy
+737,061
New +$20.8M 19.96% 2

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Lynx1 Capital Management's TVTX Position: Q2 2022 in Review

Lynx1 Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2022, closing a stake of 411,680 shares — an estimated $10.6M sold.

Lynx1 Capital Management first reported a position in TVTX in Q4 2021 and held it in 2 quarters. The position peaked at $22.9M in Q4 2021. 171 funds tracked by Wall St. Rank hold TVTX as of Q2 2022.

  • Lynx1 Capital Management reported no remaining Travere Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Lynx1 Capital Management sold 411,680 Travere Therapeutics shares in Q2 2022, an estimated $10.6M.
  • Lynx1 Capital Management first reported a position in Travere Therapeutics in Q4 2021 and held it in 2 quarters.
  • Lynx1 Capital Management's Travere Therapeutics position peaked at $22.9M in Q4 2021.
  • 171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2022.

Based on Lynx1 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.